"May 04, 2021 10.28am
Astrazenica's Farxiga claims first SGLT2 kidney disease OK from FDA.
Astrazenica is already seeing sales rocket for its' SGLT2 inhibitor Farxiga in heart failure and is expected to gather even more momentum after claiming FDA approval in CKD.
The US regulator has cleared Farxiga to reduce the risk of kidney damage,end-stage kidney disease,cardiovascular,death and hospitalisation for heart failure in adults with CKD who are at risk of progression."
GR8 news for us ....it shows this space is still a world priority.
"37 million people in the US alone with CKD"
Ann: Proteomics files US FDA 513(g) regulatory submission, page-28
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
36.0¢ |
Change
0.005(1.41%) |
Mkt cap ! $58.86M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.0¢ | 35.5¢ | $116.7K | 323.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 13166 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 113491 | 3 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| PIQ (ASX) Chart |